Oral Genome is revolutionizing preventive healthcare with its extremely delicate and particular saliva-based, periodontal caries (tooth decay), and diabetes screening take a look at, delivering outcomes that exceed {industry} requirements. With 89.7% sensitivity and 95% specificity, Oral Genome ensures correct illness detection, minimal false positives, and industry-leading reliability.
Not like early Covid-19 checks that confronted scrutiny for inconsistent outcomes, Oral Genome’s rigorous laboratory validation and medical pilot program verify its precision. The gadget precisely identifies key biomarkers, together with MMP-8 and P. gingivalis, essential for diagnosing periodontal illness and caries — all in a single, non-invasive take a look at.
Confirmed Accuracy Past Trade Requirements
Sensitivity: 89.7% – Minimizes false negatives for dependable detection.
Specificity: 95% – Distinguishes disease-free people with confidence.
Medical Validation – Outperforms commonplace FDA and EU diagnostic accuracy necessities.
“Our purpose is to set a brand new benchmark in salivary diagnostics, making certain sufferers and suppliers belief the outcomes,” stated Dr. Tina Noticed, CEO. “Oral Genome eliminates uncertainty, delivering cost-effective level of care salivary testing in preventive healthcare.”
As demand for dependable, non-invasive diagnostics grows, Oral Genome is main the best way. Its cutting-edge expertise and affordability place it for widespread adoption, remodeling oral and systemic well being monitoring.
For extra data, go to www.oralgenome.com or contact [email protected].
Junevity, a biotech that focuses on longevity by creating what they describe as “cell reset therapeutics”, has raised $10 million in seed funding. Goldcrest Capital and Godfrey Capital led the funding spherical. Its expertise depends on licensed analysis by co-founder Dr. Janine Sengstack on the College of California at San Francisco, in keeping with a press launch.
Junevity makes use of large-scale human knowledge and AI to determine genes or transcription elements that may regulate cell harm and develops siRNA therapeutics towards these targets to return cells to well being. Its preliminary therapeutics beneath growth will deal with Sort 2 diabetes, weight problems and frailty.
To learn extra, click on right here.
Coral, a Canadian digital care startup supporting ladies getting into perimenopause and menopause, has accomplished a $2.9 million ($4.1 million CAD) seed funding spherical. Brightspark Ventures led the spherical, with participation from Diagram, The51 Ventures, and angel traders. Coral will use the recent capital to assist built-in, customized options for care navigation for ladies.
To learn extra, click on right here.
Keragon, an AI-powered HIPAA-compliant automation platform for healthcare, has raised $7.5 million in a seed funding spherical. Upfront Ventures led the spherical with traders Afore Capital, Focal, and 25m Well being including to their preliminary investments. To this point, Keragon has raised a complete of $10.5 million. The no-code workflow automation platform launched out of stealth in June 2024, in keeping with a press launch.
To learn extra, click on right here.
The MedCity INVEST Pitch Excellent contest is at present accepting purposes from startups throughout digital well being, medtech, diagnostics and biopharma. The competition gives the chance for healthcare entrepreneurs to pitch to an viewers of healthcare traders and stakeholders. The convention might be held on the Willis Tower in Chicago on Could 20 and 21. The deadline for purposes is February 21.
To overview the standards and submit an software, click on right here.
Credit score: Getty Pictures, pixelliebe
It is a paid member function of MedCitizens. Please submit right here and be a part of!
